ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Attovia Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$13.89+0.16 (+1.17%)
Close on Oct 19, 2026
- Market cap
- $58.86M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Sep 2, 2026 | After market close | $500.00K | $-4.88 | – |
Press releases
Announcements Attovia Therapeutics filed with the SEC
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K